See more : DTRT Health Acquisition Corp. (DTRT) Income Statement Analysis – Financial Results
Complete financial analysis of ERYTECH Pharma S.A. (ERYP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ERYTECH Pharma S.A., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Braemar Plc (BSEAF) Income Statement Analysis – Financial Results
- GMO Payment Gateway, Inc. (GMYTF) Income Statement Analysis – Financial Results
- GVIC Communications Corp. (GCT.TO) Income Statement Analysis – Financial Results
- Myrexis, Inc. (MYRX) Income Statement Analysis – Financial Results
- Tenma Corporation (7958.T) Income Statement Analysis – Financial Results
ERYTECH Pharma S.A. (ERYP)
About ERYTECH Pharma S.A.
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 3.36M | 4.14M | 3.36M | 19.72M | 10.78M | 6.61M | 1.80M | 3.46M |
| Cost of Revenue | 0.00 | 0.00 | 57.58M | 52.19M | 33.47M | 25.46M | 19.72M | 10.78M | 6.61M | 5.33M | 3.46M |
| Gross Profit | 0.00 | 0.00 | -57.58M | -48.83M | -29.33M | -22.10M | 0.00 | 0.00 | 0.00 | -3.53M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | -1,451.52% | -708.80% | -656.90% | 0.00% | 0.00% | 0.00% | -195.63% | 0.00% |
| Research & Development | 19.91M | 45.10M | 57.58M | 52.19M | -19.72M | -25.46M | 0.00 | 0.00 | 0.00 | 2.50M | 0.00 |
| General & Administrative | 13.89M | 15.10M | 14.97M | 17.16M | 14.60M | 8.52M | 6.66M | 7.62M | 4.36M | 3.55M | 3.30M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.89M | 15.10M | 14.97M | 17.16M | 14.60M | 8.52M | 6.66M | 7.62M | 4.36M | 3.55M | 3.30M |
| Other Expenses | -6.65M | -3.69M | -3.72M | -5.28M | -4.45M | -3.10M | -3.99M | -2.81M | -2.03M | -4.29M | -5.68M |
| Operating Expenses | 27.15M | 56.52M | 68.83M | 64.07M | 10.15M | 5.43M | 2.67M | 4.81M | 2.34M | 1.76M | -2.39M |
| Cost & Expenses | 27.15M | 56.52M | 68.83M | 64.07M | 43.62M | 30.89M | 22.39M | 15.58M | 8.95M | 7.09M | 1.07M |
| Interest Income | 4.45M | 13.00K | 889.00K | 2.95M | 163.00K | 405.00K | 545.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.36M | 2.14M | 5.35M | 1.53M | 9.00K | 15.00K | 4.00K | 5.00K | 6.80K | 4.66K | 9.38K |
| Depreciation & Amortization | -19.90M | 9.06M | 889.00K | 2.95M | 797.00K | 532.00K | 425.00K | 288.00K | 276.52K | 180.30K | 292.09K |
| EBITDA | -22.69M | -47.46M | -67.94M | 5.28M | 4.45M | 3.36M | -21.47M | -14.72M | -8.60M | -8.00M | -1.86M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -1,817.09% | -904.20% | -980.56% | -108.90% | -136.63% | -130.00% | -443.87% | -53.83% |
| Operating Income | -2.80M | -56.52M | -68.83M | -64.07M | -43.62M | -30.89M | -22.39M | -15.58M | -8.95M | -7.09M | -1.07M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -1,904.70% | -1,054.16% | -918.22% | -113.55% | -144.61% | -135.32% | -393.13% | -31.04% |
| Total Other Income/Expenses | 3.09M | 2.72M | -4.47M | -67.94M | -42.67M | -2.64M | 488.00K | 567.00K | 68.17K | -1.10M | -1.09M |
| Income Before Tax | 293.00K | -53.80M | -73.30M | -62.66M | -38.22M | -33.53M | -21.90M | -15.02M | -8.88M | -8.18M | -2.16M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -1,862.66% | -923.68% | -996.82% | -111.07% | -139.35% | -134.29% | -454.14% | -62.54% |
| Income Tax Expense | 521.00K | 2.00K | 3.00K | -1.00K | 2.00K | -3.00K | 10.00K | -3.00K | -20.16K | -40.02K | 7.64K |
| Net Income | -228.00K | -53.80M | -73.30M | -62.66M | -38.22M | -33.53M | -21.91M | -15.01M | -8.86M | -8.14M | -2.17M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -1,862.63% | -923.73% | -996.73% | -111.13% | -139.32% | -133.98% | -451.92% | -62.77% |
| EPS | -0.01 | -2.27 | -3.99 | -3.49 | -2.13 | -1.87 | -2.74 | -2.16 | -1.51 | -1.74 | -0.39 |
| EPS Diluted | -0.01 | -2.27 | -3.99 | -3.49 | -2.13 | -1.87 | -2.74 | -2.16 | -1.51 | -1.74 | -0.39 |
| Weighted Avg Shares Out | 31.02M | 23.69M | 18.39M | 17.94M | 17.94M | 17.94M | 7.98M | 6.96M | 5.87M | 4.69M | 5.54M |
| Weighted Avg Shares Out (Dil) | 31.02M | 23.69M | 18.39M | 17.94M | 17.94M | 17.94M | 7.98M | 6.96M | 5.87M | 4.69M | 5.54M |
ERYTECH Pharma (ERYP) Sees Hammer Chart Pattern: Time to Buy?
ERYTECH Pharma S.A. (ERYP) has been struggling lately, but the selling pressure may be coming to an end soon
ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer
ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer
ERYTECH Pharma (ERYP) Catches Eye: Stock Jumps 7.4%
ERYTECH Pharma (ERYP) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer
LYON, France and CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the completion of enrollment in...
ERYTECH to Present at the JMP Securities Hematology Summit
LYON, France and CAMBRIDGE, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announce d today that CEO, Gil Beyen,...
Monthly information related to total number of voting rights and shares composing the share capital – November 30, 2020
LYON, France, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France
ERYTECH Announces Positive Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia Presented at the American Society of Hematology Annual Meeting
W ebcast today, Monday, December 7 at 4:00 pm CET/10:00 am ET
ERYTECH Announces Conference Webcast to Discuss Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia to be Presented at the American Society of Hematology 2020 Annual Meeting
Webcast scheduled for Monday, December 7 at 4:00 pm CET/10:00 am ET Webcast scheduled for Monday, December 7 at 4:00 pm CET/10:00 am ET
ERYTECH to Present at Jefferies Virtual Healthcare Conference
LYON, France and CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), announced t o day that its CEO, Gil Beyen, will present an update at the Jefferies Virtual London Healthcare Conference at 12 :00...
ERYTECH Pharma's (ERYP) CEO Gil Beyen on Q3 2020 Results - Earnings Call Transcript
ERYTECH Pharma's (ERYP) CEO Gil Beyen on Q3 2020 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports